Literature DB >> 8274608

Toxoplasmosis in patients with cancer.

D M Israelski1, J S Remington.   

Abstract

The unusual occurrence, protein manifestations, and often devastating consequences of toxoplasmosis in patients with cancer emphasize the need for clinical acumen in the diagnosis and management of this disorder. Toxoplasmosis in patients with cancer has most commonly been described in association with Hodgkin's disease. It has also been reported, usually in the setting of treatment with antineoplastic agents, in patients with other lymphoproliferative disorders, hematologic malignancies, and solid tumors. In this review, among patients for whom the diagnosis was made early enough to begin specific treatment, conditions of 68% improved; this finding was in marked contrast to the severe morbidity and mortality observed for untreated individuals. The high mortality in the untreated group reflects the general debilitation and severe immunocompromise of these patients. Therefore, although toxoplasmosis contributed to a poor prognosis, it was not necessarily always the proximate cause of death.

Entities:  

Mesh:

Year:  1993        PMID: 8274608     DOI: 10.1093/clinids/17.supplement_2.s423

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  48 in total

Review 1.  Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma.

Authors:  Christopher A Hunter; Linda A Lieberman; Nicola Mason; Marion Pepper; Sarah L Sague; Cristina Tato; Valerie Zediak
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  The Toxoplasma gondii rhoptry protein ROP4 is secreted into the parasitophorous vacuole and becomes phosphorylated in infected cells.

Authors:  Kimberly L Carey; Artemio M Jongco; Kami Kim; Gary E Ward
Journal:  Eukaryot Cell       Date:  2004-10

3.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

Review 4.  Long-Term Relationships: the Complicated Interplay between the Host and the Developmental Stages of Toxoplasma gondii during Acute and Chronic Infections.

Authors:  Kelly J Pittman; Laura J Knoll
Journal:  Microbiol Mol Biol Rev       Date:  2015-12       Impact factor: 11.056

5.  Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT.

Authors:  Soumya G Remesh; Massimo Andreatta; Ge Ying; Thomas Kaever; Morten Nielsen; Curtis McMurtrey; William Hildebrand; Bjoern Peters; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

6.  Improved diagnosis of reactivated toxoplasmosis.

Authors:  D Ashburn; M M Davidson; A W Joss; T H Pennington; D O Ho-Yen
Journal:  Mol Pathol       Date:  1998-04

7.  A novel dense granule protein, GRA41, regulates timing of egress and calcium sensitivity in Toxoplasma gondii.

Authors:  Kaice A LaFavers; Karla M Márquez-Nogueras; Isabelle Coppens; Silvia N J Moreno; Gustavo Arrizabalaga
Journal:  Cell Microbiol       Date:  2017-05-17       Impact factor: 3.715

8.  GABARAPL2 Is Critical for Growth Restriction of Toxoplasma gondii in HeLa Cells Treated with Gamma Interferon.

Authors:  Zhaoxia Zhang; Haorong Gu; Qi Li; Jun Zheng; Shinuo Cao; Changjiang Weng; Honglin Jia
Journal:  Infect Immun       Date:  2020-04-20       Impact factor: 3.441

9.  Seroprevalence and molecular evaluation of toxoplasmosis in children with cancer in Khuzestan province, Southwest of Iran.

Authors:  Jasem Saki; Sanaz Tavakoli; Mohammad Pedram
Journal:  J Parasit Dis       Date:  2017-04-10

10.  Disseminated toxoplasmosis in a patient with non-Hodgkin lymphoma.

Authors:  M A Herold; R Kühne; M Vosberg; S Ostheeren-Michaelis; P Vogt; U Karrer
Journal:  Infection       Date:  2009-12       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.